Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $246.00
by Amy Steele · The Cerbat GemNeurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its price target boosted by analysts at Citigroup from $242.00 to $246.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Citigroup’s target price would suggest a potential upside of 69.02% from the company’s previous close.
Several other research analysts have also weighed in on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Neurocrine Biosciences from $176.00 to $177.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Wall Street Zen upgraded Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 25th. Canaccord Genuity Group boosted their price target on Neurocrine Biosciences from $164.00 to $200.00 and gave the stock a “buy” rating in a research report on Tuesday, April 7th. Morgan Stanley raised their price objective on Neurocrine Biosciences from $173.00 to $185.00 and gave the company an “equal weight” rating in a research report on Friday, April 10th. Finally, HC Wainwright lifted their target price on Neurocrine Biosciences from $192.00 to $215.00 and gave the stock a “buy” rating in a research note on Tuesday, April 7th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $183.00.
Read Our Latest Stock Report on NBIX
Neurocrine Biosciences Stock Up 7.8%
Shares of NASDAQ NBIX traded up $10.48 during trading hours on Wednesday, hitting $145.54. The company had a trading volume of 1,384,709 shares, compared to its average volume of 1,151,320. Neurocrine Biosciences has a 1-year low of $115.66 and a 1-year high of $160.18. The firm’s 50 day moving average is $130.37 and its 200-day moving average is $137.72. The stock has a market capitalization of $14.64 billion, a P/E ratio of 31.23, a price-to-earnings-growth ratio of 0.67 and a beta of 0.34.
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last issued its earnings results on Wednesday, February 11th. The company reported $1.88 earnings per share for the quarter, missing analysts’ consensus estimates of $2.36 by ($0.48). Neurocrine Biosciences had a return on equity of 16.48% and a net margin of 16.73%.The firm had revenue of $805.50 million for the quarter, compared to analyst estimates of $804.21 million. During the same quarter in the previous year, the firm posted $1.69 earnings per share. Neurocrine Biosciences’s quarterly revenue was up 28.3% on a year-over-year basis. On average, sell-side analysts predict that Neurocrine Biosciences will post 6.57 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of NBIX. JPMorgan Chase & Co. lifted its position in Neurocrine Biosciences by 11.0% during the third quarter. JPMorgan Chase & Co. now owns 4,730,152 shares of the company’s stock worth $664,019,000 after purchasing an additional 468,405 shares during the period. AQR Capital Management LLC increased its holdings in Neurocrine Biosciences by 18.0% in the 4th quarter. AQR Capital Management LLC now owns 3,271,706 shares of the company’s stock valued at $462,652,000 after buying an additional 498,058 shares during the period. Geode Capital Management LLC raised its position in shares of Neurocrine Biosciences by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 2,059,282 shares of the company’s stock valued at $291,342,000 after buying an additional 34,457 shares in the last quarter. Los Angeles Capital Management LLC lifted its holdings in shares of Neurocrine Biosciences by 7.4% during the 4th quarter. Los Angeles Capital Management LLC now owns 1,291,278 shares of the company’s stock worth $178,248,000 after acquiring an additional 88,522 shares during the period. Finally, Northern Trust Corp lifted its holdings in shares of Neurocrine Biosciences by 31.9% during the 4th quarter. Northern Trust Corp now owns 1,221,184 shares of the company’s stock worth $173,201,000 after acquiring an additional 295,470 shares during the period. Institutional investors and hedge funds own 92.59% of the company’s stock.
Trending Headlines about Neurocrine Biosciences
Here are the key news stories impacting Neurocrine Biosciences this week:
- Positive Sentiment: Q1 results beat expectations: revenue of $811.0M (up ~44% YoY), EPS ahead of estimates, INGREZZA sales described as a key driver, and management reaffirmed 2026 INGREZZA net sales guidance of $2.7–$2.8B — a core reason investors are buying the stock. Neurocrine Q1 2026 Financial Results
- Positive Sentiment: Acquisition announced: Neurocrine agreed to acquire Soleno Therapeutics (includes VYKAT XR for hyperphagia in Prader‑Willi), expanding commercial footprint and pipeline — adds potential new revenue stream and diversification. Acquisition Announcement
- Positive Sentiment: Multiple bullish analyst moves: Piper Sandler raised its PT to $207 (overweight), RBC raised its PT to $180 (outperform), Wedbush to $176 (outperform), and Guggenheim reaffirmed a $175 buy — collectively pushing consensus upside and supporting today’s rally. Analyst Price Target Raises
- Positive Sentiment: Peer‑reviewed guidance for CRENESSITY adoption published: expert recommendations in The Journal of Clinical Endocrinology & Metabolism give clinicians practical algorithms to reduce glucocorticoid dosing after starting CRENESSITY, which should help real‑world uptake and positioning in CAH. CRENESSITY Publication
- Neutral Sentiment: Investor outreach: management will present at the Bank of America Health Care Conference (May 12), offering more visibility on execution and the 2027 outlook — a near‑term event investors will watch. BofA Conference Notice
- Neutral Sentiment: Earnings materials/transcript available: slide deck and call transcripts provide detail on drivers (INGREZZA, CRENESSITY launch, pipeline moves) for investors who want to dig into unit economics and margin trajectory. Q1 Slide Deck
- Negative Sentiment: Some market commentary questions valuation/positioning after recent gains — a Yahoo piece asks whether the stock is pricing in too much caution, signaling there are analysts/commentators worried about upside already being in the price. Yahoo Valuation Piece
About Neurocrine Biosciences
Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.
The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.